

BRINGING

HOPE

2022 Annual Report




MARY CROWLEY
CANCER RESEARCH
HOPE LIVES HERE™

MISSION STATEMENT

To bring hope to cancer patients through innovative clinical trials while advancing treatment for patients in the future.

BY THE NUMBERS



16,900,000+

U.S. CANCER SURVIVORS¹

1. Cancer Statistics 2019, National Cancer Institute

OVERALL CANCER DEATH RATES DECLINE

FROM 1991- 2019
CANCER DEATH RATES DROPPED BY
32%¹



788

OF TRIALS
MANAGED
1997-2022



7576

OF PATIENTS
ENROLLED
1997-2022



7

MEDICAL DOCTORS

3

INVESTIGATORS



20

MCCR CONTRIBUTED
TO THE DEVELOPMENT OF
20 FDA-APPROVED DRUGS

- | | |
|---------------|------------------|
| 1. BAVENCIO | 11. IMFINZI |
| 2. ROZLYTREK | 12. PEMAZYRE |
| 3. LIBTAYO | 13. SOTORASIB |
| 4. CABOMETYX | 14. NIRAPARIB |
| 5. LYNPARZA | 15. TAZEMETOSTAT |
| 6. NINLARO | 16. ABEMACICLIB |
| 7. PROVENGE | 17. LENVIMA |
| 8. YERVOY | 18. YONDELIS |
| 9. IMLYGIC | 19. FUTIBATINIB |
| 10. CAMPOSTAR | 20. ADAGRASIB |



TOP TEN TUMOR TYPES SEEN

AT MARY CROWLEY

- | | |
|------------------------|----------------|
| 1. COLON & RECTAL | 6. PROSTATE |
| 2. PANCREATIC | 7. SARCOMA |
| 3. NON-SMALL CELL LUNG | 8. ENDOMETRIAL |
| 4. OVARIAN | 9. GASTRIC |
| 5. BREAST | 10. ESOPHAGEAL |



PARTNERED WITH **329**

LEADING GLOBAL
PHARMACEUTICAL COMPANIES



155+

FIRST IN HUMAN TRIALS
CONDUCTED AT MARY CROWLEY

591

NEW PATIENT REFERRALS



60+

TRIALS OPEN AT ANY
GIVEN TIME IN 2022



A MESSAGE FROM ROY LAMKIN

Chair of the Board of Directors

Building Upon a Foundation of Excellence

2022 was another year of continued growth in performance as we expanded our ability to offer HOPE to late-stage cancer patients with an increase in our leadership position on genomic trials and a formal affiliation with Urology Clinics of North Texas (UCNT) to focus on offering an increasing number of new prostate cancer trials at their locations.

Because of our constant focus on efficiency and quality of care, we continued to improve our financial performance and the resulting strong cash position has enabled us to strengthen our ability to offer more genomic based trials and to initiate our “Mary Crowley Site Network” expansion. Beginning with UCNT we have developed the ability to partner with local practitioners to offer Mary Crowley processes, procedures, and personnel expertise at their locations, making late-stage cancer trials available to their patients at their home offices. This can provide both an even more comfortable patient-oncologist relationship because of an already existing one and expand the offering of new trials to new locations with the well-established Mary Crowley quality of care and relationship with the providers of the trials.

2023 will provide another year of growth opportunity to offer more HOPE to late-stage cancer patients as we look to further deploy the “Mary Crowley Site Network” approach to offer trials at various oncologist home sites in the Dallas-Fort Worth metroplex and beyond. As always, I encourage you to read the personal stories of some of our patients and caregivers in this report and on our website to better understand the impact that Mary Crowley is having by providing “HOPE to cancer patients through innovative clinical trials while advancing treatment for patients in the future.”



MARY CROWLEY MEDICAL RESEARCH CENTER AND AFFILIATES

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

As of December 31, 2022 and 2021

Assets

CURRENT ASSETS	2022	2021
Cash and cash equivalents	\$ 7,888,850	\$ 6,995,987
Investments in securities	1,861,606	1,779,317
Accounts receivable	5,625,865	5,380,609
Contributions receivable	173,713	3,950
Prepaid expenses & other current assets	288,029	48,414
Total current assets	15,838,063	14,208,277
PROPERTY AND EQUIPMENT (NET)	444,370	296,247
OTHER ASSETS		
Deposits	30,432	30,432
Right-of-use asset	7,383,184	
Total other assets	7,413,616	30,432
TOTAL ASSETS	23,696,049	14,534,956

Liabilities and Net Assets

CURRENT LIABILITIES		
Accounts payable	1,468,319	1,525,265
Accrued expenses	2,321,427	1,462,979
Contract Liabilities	12,000	12,000
Current portion of long-term lease liability - operating lease	660,392	
Total current liabilities	4,462,138	3,000,244
LONG-TERM LIABILITIES		
SBA Loans		10,000
Long-term portion of lease liability - operating lease	7,057,132	
Total long-term liabilities	7,057,132	10,000
TOTAL LIABILITIES	11,519,270	3,010,244
NET ASSETS		
Without Donor Restrictions		
General unrestricted	7,756,835	8,279,760
Board designated	2,165,062	1,852,184
Total without donor restrictions	9,921,897	10,131,944
With Donor Restrictions	2,254,882	1,392,768
Total net assets	12,176,779	11,524,712
TOTAL LIABILITIES AND NET ASSETS	23,696,049	14,534,956

MARY CROWLEY MEDICAL RESEARCH CENTER AND AFFILIATES

CONSOLIDATED STATEMENT OF ACTIVITIES

For the Year Ended December 31, 2022
With summarized financial information for the year ended December 31, 2021

	Without Donor Restriction	With Donor Restriction	Total All Funds	
			2022	2021
SUPPORT AND REVENUE:				
Revenue - Contracts with customers	\$ 13,483,102	-	13,483,102	11,593,244
Research revenue				
Contribution and grant revenue	263,860	1,637,430	1,901,290	1,363,559
Interest income	52,941	-	52,941	35,465
Realized gain on investments	42,631	-	42,631	41,163
Unrealized gain (loss) on investments	(341,189)	-	(341,189)	229,956
Net assets released from restrictions	775,316	(775,316)	-	-
Total support and revenue	14,276,661	862,114	15,138,775	13,263,387
OPERATING EXPENSES:				
Program				
Medical & research	11,555,220	-	11,555,220	9,468,935
General & administrative	2,523,764	-	2,523,764	2,280,444
Fundraising	445,232	-	445,232	435,100
Total operating expenses	14,524,216	-	14,524,216	12,184,479
Changes in net assets from operations	(247,555)	862,114	614,559	1,078,908
Other income (expense)	37,508	-	37,508	6,810
CHANGE IN NET ASSETS	(210,047)	862,114	652,067	1,085,718
NET ASSETS, beginning of period	10,131,944	1,392,768	11,524,712	10,438,994
NET ASSETS, end of period	9,921,897	2,254,882	12,176,779	11,524,712

Donor Spotlight: Pushing Hope ***Annual Marine Industry Charity Tournament***

Every year, a big pink barge embarks on an expedition to raise cancer awareness. Parading up and down the Mississippi River, the stark contrast of bright pink paint gliding through muddy waters commands the attention of onlookers. Big Hope 1 travels inland waterways as a bright pink beacon of hope for all to see.

Painted pink for cancer awareness by Ceres Consulting LLC and Ceres Barge Line, Big Hope 1 has generated more than \$1.7 million in donations for Mary Crowley Cancer Research since 2012. Big Hope 1's annual expedition has been accompanied by the Pushing Hope Annual Marine Industry Charity Tournament, a fundraiser that has faithfully supported Mary Crowley Cancer Research for 11 years straight.

Ceres Barge Line employee, Vince Schu, initiated efforts to bring cancer awareness to the forefront of the barge and towing industry, pioneering the idea of Big Hope 1. Having been deeply affected by cancer, as had many of his colleagues and friends, Vince voiced the idea of Ceres supporting cancer research, and the team enthusiastically agreed. They decided to create a vessel that could command cancer awareness with its mere presence and did so by painting a barge bright pink. Sherwin-Williams generously agreed to donate the signature bright pink paint, and Jeff Boat Shipyard agreed to paint the barge. The vessel's name, Big Hope 1, was selected to represent the HOPE that treatment gives to advanced cancer patients at Mary Crowley. In 2012, Ceres launched Big Hope 1, the big pink barge, on the expedition of raising cancer awareness and supporting cancer research at Mary Crowley Cancer Research.

"The marine industry is a group of individuals who do not sit back and wait for someone else to solve a problem. Instead, we take the problem on head first and try to tackle it with whatever resources we have available," Ceres Officers Mark Fletcher and Mark Mestemacher explain. "BIG HOPE 1 unites and rallies the

inland river and coastal regions and affiliated industries in fighting a disease that strikes all ages, races and genders without remorse. This fundraising effort shows firsthand how that 'can-do' attitude can work toward a common good."

In fact, Ceres goes beyond simply raising awareness by raising funds to support clinical trials at Mary Crowley Cancer Research. Each year, they host the Pushing Hope Annual Marine Industry Charity Tournament, a fun event featuring activities such as seafood boil, golf tournament, and cornhole. Members of the barge industry all over the country gather in support of their family and friends who have been affected by cancer, while enjoying a chance to socialize with their associates. After approaching Mary Crowley, an agreement was made that Mary Crowley would be supported for a handful of years before the event would benefit another foundation. This transition never occurred, and Ceres has faithfully continued to exclusively support Mary Crowley with their Pushing Hope fundraising event.

Again, thanks to the generous efforts of Ceres, the rest of the barge industry, and the Big Hope 1 initiative for raising over \$1.7 million since 2012. Mary Crowley is so grateful for their support, which has allowed us to open even more clinical trials and support countless patients. Because of Big Hope 1, new cancer treatments have been approved by the FDA and are now available to all cancer patients that were not available previously. Cancer patients have HOPE everyday thanks to Big Hope 1!



Raymond Wong's Caregiver Journey



Raymond Wong's mother Lily Wong first came to America from China in 1976, now retired after more than 20 years in the restaurant business. When Lily first started having pain and symptoms, her son urged her to have a colonoscopy, which ultimately led to her diagnosis of stage 4 colon cancer in May 2021.

Lily and Raymond faced challenges in treating her cancer not only due to its advanced nature, but also due to cultural differences between the two generations, "My Mom has a hesitation to Western medicine, whereas I am on the side of science," said Raymond.

By the end of the year, Lily's cancer was no longer responding to the chemotherapy, so her oncologist ran a report of her tumor's genetic markers to see if a clinical trial might be the right fit for her. After evaluating trial options in both the Houston and Dallas areas, Raymond and Lily settled on Mary Crowley Cancer Research and enrolled in Trial #18-26 in March 2022.

Lily's trial is for the drug Adagrasib, a small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C. Upon oral administration, Adagrasib binds to KRAS G12C and inhibits mutant KRAS-dependent signaling.

Since then, Raymond drives up from Austin every other week to help translate for his mother as she receives her half-day of infusion treatment at Mary

Crowley. "Our experience has been very positive," said Raymond. "All the staff has been very helpful. They answered all our questions, and, in the beginning, you have thousands of them."

Lily has been fortunate to experience very minimal and mild side effects, allowing her full functionality to still participate in activities she loves such as gardening.

But Raymond has faced new challenges now as a caregiver. Beyond getting his mother's affairs in order, he has been aiding her in all her appointment scheduling and making sure she takes all her medications properly.

But he continues to support her as she goes through treatment. "I push her to continue the trial for the benefit of the next generation, just as she is benefitting from others going through it before her. We are lucky that she is not as bad off as others," stated Raymond.

"We saw an immediate benefit from treatment when we started with Mary Crowley, my mother knows how she felt when her prior treatment stopped working and she doesn't want to go downhill again. Seeing her doing so much better, I can sleep at night," said Raymond.

"I was very scared, nervous and upset when I received my diagnosis," Raymond translated from Lily. "Now I am much better, more positive and confident." oth had high praise for the Mary Crowley staff, Lily stating, "the staff is very friendly and helpful. They make it so much easier to handle."

OUR LEADERSHIP

Jennifer Fox, Chief Executive Officer

Minal Barve, M.D., Executive Medical Director

Deborah Montonen, CFRE, Vice President and Chief Development Officer

Stacy Meador - Vice President of Finance

Natalie Settele, Vice President of Clinical Research Operations

BOARD OF TRUSTEES

Roy Lamkin, Board Chair

Scott Bradley Burris, M.D., Board Vice Chair

Adil Adi

Vincent Bush

Ron Carter

Edwin Flores, J.D., PhD

Jennifer Fox

Thomas B. Hoyt

Tom Hulsey

Michael Kearins

Edward W. Marx

Rodney G. Olsen

Mary Elizabeth Warner, J.D.

MEDICAL STAFF

Minal Barve, M.D., Executive Medical Director

James Strauss, M.D., Clinical Scientific Director

Reva Schneider, M.D., Physician Investigator

Jairo Olivares, M.D., Physician Investigator

Douglas Orr, M.D., Physician Investigator

Gilberto Jimenez-Justiniano, M.D., FACP, Physician Investigator

Leah Plato, P.A., Associate Director of Clinical and Scientific Operations

Zoey Sayi, Nurse Practitioner

Jenifer Mallow, Nurse Practitioner